Simone Périnet, Anson Williams, Laurence Campeau, Janelle Elliott, Fan Zhang, Qiuying Yang, Joseph Cox, Karelyn Davis, Jordan J Feld, Marina B Klein, Nadine Kronfli, Mia J Biondi, Peter K Daley, Nashira Popovic
{"title":"National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.","authors":"Simone Périnet, Anson Williams, Laurence Campeau, Janelle Elliott, Fan Zhang, Qiuying Yang, Joseph Cox, Karelyn Davis, Jordan J Feld, Marina B Klein, Nadine Kronfli, Mia J Biondi, Peter K Daley, Nashira Popovic","doi":"10.14745/ccdr.v51i67a02","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of morbidity and mortality worldwide. Measuring the epidemiological burden of HCV and HBV in Canada is essential to measure progress towards global elimination targets and to ultimately eliminate viral hepatitis as a public health concern.</p><p><strong>Objective: </strong>This study aimed to provide the first national estimates of HBV prevalence and unawareness, and to update estimates of HCV incidence, prevalence, and unawareness in the general population and key populations in Canada for 2021. Progress towards elimination targets for 2025, namely incidence, awareness, mortality, and HBV vaccination, was also assessed.</p><p><strong>Methods: </strong>A combination workbook method and mathematical modelling was used to estimate the prevalence and unawareness of chronic hepatitis B (CHB), prevalence and incidence of anti-HCV antibodies, and the prevalence and unawareness of chronic hepatitis C (CHC).</p><p><strong>Results: </strong>The estimated prevalence of CHB was 0.68% (plausible range: 0.40%-0.97%) or 262,000 (152,000-371,000) people in the general population, of whom 42.5% (33.9%-51.0%) were unaware of their infection. Immigrants from countries where HBV is common had the highest prevalence at 4.2% (1.9%-5.6%). An estimated 8,212 new HCV infections occurred in 2021, and the estimated prevalence of CHC was 0.56% (0.15%-0.97%) or 214,000 (58,500-369,000) people, of whom 41.5% (34.3%-48.8%) were unaware of their infection. People who inject drugs had the highest prevalence and largest proportion who were unaware at 36.9% (12.6%-55.1%) and 49.9% (29.0%-70.2%), respectively.</p><p><strong>Conclusion: </strong>While the overall viral hepatitis burden is low in the general Canadian population, these estimates indicate that certain populations and communities remain disproportionately affected. Although Canada has met some of the 2025 targets, more work is needed. To this end, efforts to obtain and standardize provincial and national data will be required to measure progress towards all elimination targets.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"51 6-7","pages":"223-237"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372649/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canada communicable disease report = Releve des maladies transmissibles au Canada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14745/ccdr.v51i67a02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of morbidity and mortality worldwide. Measuring the epidemiological burden of HCV and HBV in Canada is essential to measure progress towards global elimination targets and to ultimately eliminate viral hepatitis as a public health concern.
Objective: This study aimed to provide the first national estimates of HBV prevalence and unawareness, and to update estimates of HCV incidence, prevalence, and unawareness in the general population and key populations in Canada for 2021. Progress towards elimination targets for 2025, namely incidence, awareness, mortality, and HBV vaccination, was also assessed.
Methods: A combination workbook method and mathematical modelling was used to estimate the prevalence and unawareness of chronic hepatitis B (CHB), prevalence and incidence of anti-HCV antibodies, and the prevalence and unawareness of chronic hepatitis C (CHC).
Results: The estimated prevalence of CHB was 0.68% (plausible range: 0.40%-0.97%) or 262,000 (152,000-371,000) people in the general population, of whom 42.5% (33.9%-51.0%) were unaware of their infection. Immigrants from countries where HBV is common had the highest prevalence at 4.2% (1.9%-5.6%). An estimated 8,212 new HCV infections occurred in 2021, and the estimated prevalence of CHC was 0.56% (0.15%-0.97%) or 214,000 (58,500-369,000) people, of whom 41.5% (34.3%-48.8%) were unaware of their infection. People who inject drugs had the highest prevalence and largest proportion who were unaware at 36.9% (12.6%-55.1%) and 49.9% (29.0%-70.2%), respectively.
Conclusion: While the overall viral hepatitis burden is low in the general Canadian population, these estimates indicate that certain populations and communities remain disproportionately affected. Although Canada has met some of the 2025 targets, more work is needed. To this end, efforts to obtain and standardize provincial and national data will be required to measure progress towards all elimination targets.